CD8A and neoplasm: We found that CD4+, CD8+ and epitope specific CD8+ T cells increased per tumor weight in the aFP-treated groups (CD3/weight and CD8/weight: control vs. aFP, control vs. aFP + anti-PD-1 and anti-PD-1 vs. aFP + anti-PD-1 (p < 0.05); CD4/weight and epitope specific CD8+ T cells: control vs. aFP, control vs. aFP + anti-PD-1, anti-PD-1 vs. aFP and anti-PD-1 vs. aFP + anti-PD-1 (p < 0.05; Fig. 5a and c).